____________________________________________________________________________________________________________________________________________
Latest News:
NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide™, in support of a pre-IND Meeting. The Company anticipates that the pre-IND Meeting would take place in March-April 2012. The actual meeting date will be assigned by the FDA.
OneMedPlace Presentation Slides June 23,2011: Click here
06/20/2011 @ 7:00AM EDT WEST HAVEN, Conn., --NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it will be leasing new space for cGMP production of its nanoviricides® drug candidates against various viral diseases.
Publications:
POLYMERIC MICELLE NANOMATERIALS AS ANTIVIRAL COMPOUNDS FOR EBOLA VIRUS INFECTION
C.E. Scully1, C.M. Lear1, A.R. Diwan2, R.W. Barton2, J.G. Tatake, G.Olinger1
1 United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA
2 NanoViricides, Inc. West Haven, CT, USA,
Email: corinne.scully@us.army.mil
http://www.nnvcwebsite.com/PDF/polymeric_micelle_nanomaterials.pdf
____________________________________________________________________________________________________________________________________________
About NNVC-
NanoViricides, Inc. is a development stage, publicly traded, fully reporting company (symbol: NNVC).
It has developed a unique nanomedicine-based approach to develop novel anti-viral agents.
A NanoViricide™ is a specially designed, flexible, nanomaterial that may contain an
encapsulated active pharmaceutical ingredient and is specifically targeted to a specific
type of virus, like a guided missile. NanoViricide drugs are designed to block and
dismantle the virus particles before they can infect a cell, thereby controlling viremia.
Link to Official Company Website
MIcrographic images of nanoviricide micelles in action against Murine Cytomegalovirus: 
http://www.nanoviricides.com/nnvc-tem.pdf
Drugs in Development
Pre-Clinical Studies:
Drugs Currently Nearing IND Status:
- FluCide: Currently entering final pre-clinical testing stages
- HIV-Cide: Antiviral targeting HIV virus particles
- Dengue Antiviral/DengueCide
Drugs Currently in Pre-clinical testing:
- FluCide antiviral against HxNx (H1N1 Swine Flu, H5N1 Avi Flu, etc)
- Dengue Antiviral (UC Berkeley, Dr. Eva Harris)
- HIV-Cide (UCSF)
- EKC/Eye Herpes (Thevac, Feinstein Institute)
- HSV-1 and HSV-2 antiviral (NOUCM, Dr Ken S. Rosenthal)
- EbolaCide for Ebola (USAMRIID)
Future Studies Planned and in Development by NNVC:
Marburg
Rift Valley Fever
West Nile Fever
Junin virus
Machupo virus
Lassa Fever
Hanta Virus
CMV Eye
Hepatitis B & C
Chukungunya Fever
Delivery Methods for a nanoviricide:
- Injectables
- Bronchial Sprays
- Nasal Sprays (Nose Drops)
- Ocular (Eye Drops)
- Oral for special circumstances
- Skin Patches
NNVC Officers:
Dr. Eugene Seymour - Chief Executive and Financial Officer
Dr. Anil Diwan - Chairman of the Board of Directors and President
Dr. Jayant Tatake - Vice President of Research and Development
Dr. Randall Barton - Chief Scientific Officer
Dr. Krishna Menon - Chief Regulatory Officer
Investor Relations Contact:
NanoViricides, Inc.
Amanda Schuon
310-550-7200
info@nanoviricides.com
NNVC SI message board:
http://www.siliconinvestor.com/subject.aspx?subjectid=55797
NANOVIRICIDES, INC Quarterly Report 12-31-2011
http://www.sec.gov/Archives/edgar/data/1379006/000114420412008747/v302227_10q.htm
Share Structure as of Q report released 2-14-2012
- O/S: 151,484,142 fully diluted
- Authorized: 300 million
Transfer Agent:
www.corporatestock.com/
Daily and Weekly Charts
Allexcel Patents
1. (WO 2009/011702) SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS
The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells.
2. (WO 2008/091246 SELF-ASSEMBLING AMPHOPHILIC POLYMERS AS ANTIVIRAL AGENTS
There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds and disrupting viral coat proteins. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties which mediate adherence of the aggregate to a viral target.
3. (WO 2007/084126) SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS
There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds such as drugs, vitamins, dyes, and imaging agents. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties useful for the targeted delivery of drugs and imaging agents.
NNVC News:
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that the results of the evaluation of several of its nanoviricides® anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."
Anti-Dengue Nanoviricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever
June 21, 2010, 7:00 a.m. EDT
WEST HAVEN, Conn., Jun 21, 2010 (BUSINESS WIRE) -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley). {C}{C}{C}{C}{C}{C}{C}
Tuesday June 8, 2010, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
{C}{C}{C}{C}{C}{C}{C}
Tuesday June 1, 2010, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley).
17. May 2010 08:47
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it has signed a Research Agreement with the University of California, San Francisco (UCSF)
for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.
NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%
NanoViricides, Inc. Reports that HIVCide-I Was Significantly Superior to the Current Anti-HIV Three Drug Cocktail Standard
The Novel Mechanism of Action of HIVCide-I Defines a New Class of Anti-HIV Drugs -Monday August 11, 7:00 am ET
http://www.nanotechwire.com/news.asp?nid=6461
NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research
Study to Evaluate Usage Strategy for further Development towards Drug Approval -Monday August 4, 7:00 am ET
http://www.nanotechwire.com/news.asp?nid=6414
NanoViricide's EKC Eye Drug Candidate Stopped Clinical Conjunctivitis Pathology
Statistical Data Analysis Revealed Excellent Efficacy Using Clinical Scores in Animal Study; Confirmed Photographic Findings
http://www.medicalnewstoday.com/articles/115204.php
NanoViricides in Discussions with Pharma about EKC Eye Drug Candidate
Non-Disclosure Agreements Signed; Meetings Scheduled, says Company
http://www.drugs.com/clinical_trials/nanoviricides-discussions-pharma-ekc-eye-candidate-4445.html
NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials
First Treatment Success against a Non-Enveloped Virus
www.reuters.com/article/pressRelease/idUS103906+19-May-2008+BW20080519
Anti-HIV NanoViricide Drug Candidate Demonstrates Significant Therapeutic Efficacy in Animal Trials
Positive Initial Results Pave the Way for Definitive Follow-Up Studies
nanotechwire.com/news.asp
Nanoviricides Found Highly Effective against Ebola by USAMRIID
http://news.moneycentral.msn.com/ticker/article.aspx?symbol=US:NNVC&feed=BW&date=20080219&id=8205799
77
New Images Show Virus Dismantled by Broad-Spectrum NanoViricides
Electron Micrographs Confirm Virus Destruction
Thursday May 31, 5:45 pm ET
findarticles.com/p/articles/mi_m0EIN/is_2007_May_31/ai_n19376822
NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas
http://www.nanotechwire.com/news.asp?nid=5251&ntid=&pg=40
NanoViricides, Inc. Achieves Broad Success in Initial FluCide-I™ Anti-Influenza Studies;
Company Says That Nanoviricides™ is Now a Proven Platform To Attack Bird Flu
http://www.findarticles.com/p/articles/mi_m0EIN/is_2006_March_20/ai_n16109928